14 Sep '22
--The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms-- --Clinical Development Goals are Focused on Producing Phase 1b/Phase 2 Efficacy Readouts in Multiple Tumor Types Over the Next two Years-- WESTPORT, Conn. , Sept. 14, 2022 (GLOBE NEWSWIRE) -- Portage Biotech
08 Sep '22
WESTPORT, Conn. , Sept. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced that the Company’s management team will be presenting at the following upcoming
29 Aug '22
--Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn. , Aug.
18 Aug '22
CEO Dr. Ian Walters to take on additional responsibility as Chairman of the Board Justin Fairchild , MPH, an expert in clinical immunotherapy, appointed Vice President of Development WESTPORT, Conn. , Aug. 18, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc.
01 Aug '22
--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets-- --Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn. , Aug.
Displaying 1 - 10 of 16